Spectral Medical Brief: Loss for the Three-months Ended September 30, 2024 Was $9,995,000, $(0.04) per Share Vs Loss of $3,804,000, $(0.01) per Share for Same Period Prior Year

MT NewswiresNov 8 08:10 ET

Spectral Medical Provides August Tigris Trial Update

GlobeNewswireSep 3 07:30 ET

Earnings Flash: Spectral Medical Q2 Revenue $471,000 Up From $306,000 in 2023

MT NewswiresAug 9 08:04 ET

Spectral Medical Brief: Says Net Proceeds From Offering Expected to Be Primarily Used by the Co on Its Phase III Registration Trial (Tigris) for Its PMX Treatment for Endotoxemic Septic Shock and for General Corporate and Working Capital Purposes

MT NewswiresJul 22 08:07 ET

Spectral Medical Inc. Announces Change to Auditor

GlobeNewswireJul 11 16:00 ET

Spectral Medical Inc. Announces Results of Annual Meeting of Shareholders

GlobeNewswireJun 7 16:18 ET